Literature DB >> 11100062

Herpes simplex encephalitis occurring after chemotherapy, surgery, and stereotactic radiotherapy for medulloblastoma.

S Molloy1, D Allcutt, P Brennan, M A Farrell, R Perryman, F M Brett.   

Abstract

Reactivation of latent herpes simplex virus (HSV) in the trigeminal ganglion most commonly gives rise to recurrent herpes labialis and rarely to herpes simplex encephalitis. The mechanisms underlying reactivation of latent trigeminal HSV are complex. Here we report the case history of a 25-year-old woman who developed a fatal, bilateral necrotizing destructive temporal lobe lesion following surgical removal of a cerebellar medulloblastoma and combined radiotherapy and chemotherapy for recurrent tumor. Neuropathologic examination of the brain revealed minimal inflammatory changes, but immunohistochemistry was positive for HSV protein, and HSV deoxyribonucleic acid (DNA) was recovered from formalin-fixed paraffin-embedded brain tissue. The temporal proximity of the surgery, chemotherapy, and radiotherapy to the onset of disease suggests that these factors may have acted as triggers that precipitated conversion of latent HSV to overt HSV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100062     DOI: 10.5858/2000-124-1809-HSEOAC

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities.

Authors:  Uta K Meyding-Lamadé; Christoph Oberlinner; Philipp R Rau; Sonja Seyfer; Sabine Heiland; Johann Sellner; Brigitte T Wildemann; Wolfram R Lamadé
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

2.  Herpes simplex encephalitis in patients with cancer.

Authors:  Jerome J Graber; Marc K Rosenblum; Lisa M DeAngelis
Journal:  J Neurooncol       Date:  2011-06-03       Impact factor: 4.130

Review 3.  HSV-1 encephalitis relapse after epilepsy surgery: a case report and review of the literature.

Authors:  Vittorio Mantero; Massimo Cossu; Andrea Rigamonti; Anna Fiumani; Paola Basilico; Laura Tassi; Andrea Salmaggi
Journal:  J Neurovirol       Date:  2019-08-29       Impact factor: 2.643

4.  Fatal herpetic encephalitis during brain radiotherapy in a cerebral metastasized breast cancer patient.

Authors:  Tatiana Koudriavtseva; Emanuela Onesti; Riccardo Tonachella; Lorella Pelagalli; Antonello Vidiri; Bruno Jandolo
Journal:  J Neurooncol       Date:  2010-02-11       Impact factor: 4.130

Review 5.  Herpes simplex encephalitis following spinal ependymoma resection: case report and literature review.

Authors:  Daniel M S Raper; Alvin Wong; Paul C McCormick; Linda D Lewis
Journal:  J Neurooncol       Date:  2010-10-13       Impact factor: 4.130

6.  Herpes simplex encephalitis in patients receiving chemotherapy and whole-brain radiation therapy.

Authors:  Nir Hersh; Israel Steiner; Tali Siegal; Felix Benninger
Journal:  J Neurovirol       Date:  2021-09-21       Impact factor: 2.643

Review 7.  Herpes simplex encephalitis and subsequent cytomegalovirus encephalitis after chemoradiotherapy for central nervous system lymphoma: a case report and literature review.

Authors:  Hiroshi I Suzuki; Akira Hangaishi; Noriko Hosoya; Takuro Watanabe; Yoshinobu Kanda; Toru Motokura; Shigeru Chiba; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

8.  Effects of thyroid hormone on HSV-1 gene regulation: implications in the control of viral latency and reactivation.

Authors:  Shao-Chung Hsia; Gautam R Bedadala; Matthew D Balish
Journal:  Cell Biosci       Date:  2011-07-14       Impact factor: 7.133

Review 9.  Herpes simplex encephalitis as a complication of neurosurgical procedures: report of 3 cases and review of the literature.

Authors:  David A Jaques; Spyridoula Bagetakou; Arnaud G L'Huillier; Andrea Bartoli; Maria-Isabel Vargas; Joel Fluss; Laurent Kaiser
Journal:  Virol J       Date:  2016-05-23       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.